AR048771A1 - Composiciones para efectuar una perdida de peso - Google Patents
Composiciones para efectuar una perdida de pesoInfo
- Publication number
- AR048771A1 AR048771A1 ARP050101749A ARP050101749A AR048771A1 AR 048771 A1 AR048771 A1 AR 048771A1 AR P050101749 A ARP050101749 A AR P050101749A AR P050101749 A ARP050101749 A AR P050101749A AR 048771 A1 AR048771 A1 AR 048771A1
- Authority
- AR
- Argentina
- Prior art keywords
- weight loss
- compositions
- individual
- compound
- make
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Composiciones para efectuar una pérdida de peso que comprende un primer compuesto y un segundo compuesto, donde el primer compuesto es un agente antidiabético y el segundo compuesto es un anticonvulsivante. Métodos para efectuar una pérdida de peso, aumentar el gasto de energía, aumentar la saciedad en un individuo, o suprimir el apetito de un individuo, que comprende identificar a un individuo que lo necesita y tratar a ese individuo con un agente antidiabético y un anticonvulsivante.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56792204P | 2004-05-03 | 2004-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR048771A1 true AR048771A1 (es) | 2006-05-24 |
Family
ID=34967494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050101749A AR048771A1 (es) | 2004-05-03 | 2005-05-02 | Composiciones para efectuar una perdida de peso |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050277579A1 (es) |
EP (1) | EP1748776A1 (es) |
JP (1) | JP2007536229A (es) |
CN (1) | CN1968692A (es) |
AR (1) | AR048771A1 (es) |
AU (1) | AU2005244151A1 (es) |
BR (1) | BRPI0510593A (es) |
CA (1) | CA2565154A1 (es) |
IL (1) | IL178977A0 (es) |
MX (1) | MXPA06012685A (es) |
RU (1) | RU2006139930A (es) |
TW (1) | TW200536553A (es) |
WO (1) | WO2005110405A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101072885B1 (ko) * | 2002-05-17 | 2011-10-17 | 듀크 유니버시티 | 비만치료방법 |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
US20050089559A1 (en) * | 2003-10-23 | 2005-04-28 | Istvan Szelenyi | Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
CA2553207A1 (en) | 2004-01-13 | 2005-08-04 | Kishore M. Gadde | Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss |
US7713959B2 (en) | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
US20060100205A1 (en) * | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
JP5180092B2 (ja) | 2005-11-22 | 2013-04-10 | オレキシジェン・セラピューティクス・インコーポレーテッド | インスリン感受性を増すための組成物および方法 |
EP1991243A1 (en) * | 2006-03-08 | 2008-11-19 | HHC Formulations Ltd. | Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis |
US7960436B2 (en) * | 2006-06-05 | 2011-06-14 | Valeant Pharmaceuticals International | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
KR20090018863A (ko) * | 2006-06-08 | 2009-02-23 | 쉬바르츠파르마에이지 | 통증성 의학적 상태를 위한 치료제 조합 |
KR20150003925A (ko) * | 2006-06-15 | 2015-01-09 | 유씨비 파르마 게엠베하 | 상승적 항경련 효과를 갖는 약제학적 조성물 |
US20080045534A1 (en) * | 2006-08-18 | 2008-02-21 | Valeant Pharmaceuticals North America | Derivatives of 1,3-diamino benzene as potassium channel modulators |
US8993593B2 (en) * | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
CA2661462C (en) * | 2006-08-23 | 2015-09-29 | Valeant Pharmaceuticals International | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
EP2033656A1 (en) * | 2007-09-04 | 2009-03-11 | Stichting Top Institute Food and Nutrition | Satiety-modulating compositions for oral application |
US8722929B2 (en) * | 2006-10-10 | 2014-05-13 | Valeant Pharmaceuticals International | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators |
AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
CN101588795A (zh) | 2006-11-09 | 2009-11-25 | 奥雷西根治疗公司 | 包含中间快速溶解层的分层药物制剂 |
JP2010511052A (ja) * | 2006-11-28 | 2010-04-08 | バレアント ファーマシューティカルズ インターナショナル | カリウムチャネル調節因子としての1,4ジアミノ二環式レチガビンアナログ |
US8367684B2 (en) * | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
US7786146B2 (en) * | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
US10786464B2 (en) * | 2009-11-03 | 2020-09-29 | Lupin Limited | Modified release formulation of lacosamide |
US9492422B2 (en) | 2009-11-13 | 2016-11-15 | Toray Industries, Inc. | Therapeutic or prophylactic agent for diabetes |
EP3659604A1 (en) | 2010-01-11 | 2020-06-03 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
CN107050456B (zh) * | 2010-09-28 | 2022-08-12 | 加利福尼亚大学董事会 | 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合 |
WO2012054816A2 (en) * | 2010-10-22 | 2012-04-26 | Mitokine Bioscience, Llc | Methods of delaying and treating diabetes |
HUE049859T2 (hu) | 2012-06-06 | 2020-10-28 | Nalpropion Pharmaceuticals Llc | Készítmény magas kardiovaszkuláris kockázatnak kitett páciensekben túlsúly és elhízás kezelésére szolgáló eljárásban történõ alkalmazásra |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
JP6902033B2 (ja) | 2015-12-30 | 2021-07-14 | アダマス ファーマシューティカルズ, インコーポレイテッド | 発作−関連障害の処置のための方法および組成物 |
CA3152384A1 (en) * | 2018-09-06 | 2020-03-12 | Ian Cooke | Method of treating a sleep breathing disorder |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8800823A (nl) * | 1987-04-10 | 1988-11-01 | Sandoz Ag | Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten. |
US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
US5403595A (en) * | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5713488A (en) * | 1996-01-24 | 1998-02-03 | Farrugia; John V. | Condom dispenser |
CA2220768A1 (en) * | 1996-03-13 | 1997-09-18 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
ATE224189T1 (de) * | 1996-06-28 | 2002-10-15 | Ortho Mcneil Pharm Inc | Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit |
FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
CN1155410C (zh) * | 1997-10-03 | 2004-06-30 | 卡里药品公司 | 治疗尼古丁成瘾的含有尼古丁受体拮抗剂和抗抑郁药或抗焦虑药的组合物 |
US6262049B1 (en) * | 1997-10-28 | 2001-07-17 | Schering Corporation | Method of reducing nicotine and tobacco craving in mammals |
IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
BR9907203A (pt) * | 1998-01-21 | 2000-10-17 | Glaxo Group Ltd | "composto, composições farmacêuticas, uso de um composto, e, processo de tratametno de depressão, distúrbio de hiperatividade por deficiência de atenção (adhd), obesidade, enxaqueca, dor, disfunção sexual, doença de parkinson, doença de alzeheimer, ou vìcio de cocaìna ou de produtos contendo nicotina (especialmente tabaco) em um indivìduo animal ou humano. " |
US6048322A (en) * | 1998-04-15 | 2000-04-11 | Kushida; Clete | Morphometric measurement tool |
US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
US20030144174A1 (en) * | 1998-12-09 | 2003-07-31 | Miles B. Brennan | Methods for identifying compounds useful for the regulation of body weight and associated conditions |
US6210716B1 (en) * | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
US8545880B2 (en) * | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
WO2000059855A1 (en) * | 1999-04-01 | 2000-10-12 | Esperion Therapeutics, Inc. | Ether compounds, compositions, and uses thereof |
ES2305606T3 (es) * | 1999-04-06 | 2008-11-01 | Sepracor Inc. | Succinato de o-desmetilvenlafaxina. |
US6420369B1 (en) * | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
US7056890B2 (en) * | 1999-06-14 | 2006-06-06 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US6071918A (en) * | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
CN1406129A (zh) * | 2000-01-22 | 2003-03-26 | 艾伯特·舒尔曼 | 用于治疗物质滥用的方法 |
DE60119696T2 (de) * | 2000-03-15 | 2007-01-25 | Wolfgang Ross Sadee | Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch |
US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
EP1970072A1 (en) * | 2000-09-18 | 2008-09-17 | Sanos Bioscience A/S | Use of GLP-2 peptides for the treatment of hyperparathyroidism |
WO2002064210A2 (en) * | 2000-10-30 | 2002-08-22 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising anti-diabetic and anticonvulsant agents |
US6569449B1 (en) * | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
US20030087896A1 (en) * | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
US6481031B1 (en) * | 2001-11-14 | 2002-11-19 | In Mo Hwang | Pillow oriented for comfort in varying sleeping positions |
US20040029941A1 (en) * | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
KR101072885B1 (ko) * | 2002-05-17 | 2011-10-17 | 듀크 유니버시티 | 비만치료방법 |
US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
PT2316456T (pt) * | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
MXPA05012317A (es) * | 2003-05-16 | 2006-01-30 | Pfizer Prod Inc | Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas. |
US7759358B2 (en) * | 2003-07-23 | 2010-07-20 | Crooks Peter A | Oral bioavailable prodrugs |
WO2005049043A1 (en) * | 2003-11-18 | 2005-06-02 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising metformin and anticonvulsant agents |
CA2553207A1 (en) * | 2004-01-13 | 2005-08-04 | Kishore M. Gadde | Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
US20060100205A1 (en) * | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
US20060058293A1 (en) * | 2004-08-03 | 2006-03-16 | Eckard Weber | Combination of bupropion and a second compound for affecting weight loss |
WO2006055854A2 (en) * | 2004-11-17 | 2006-05-26 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtazapine treatment |
-
2005
- 2005-04-27 CA CA002565154A patent/CA2565154A1/en not_active Abandoned
- 2005-04-27 RU RU2006139930/15A patent/RU2006139930A/ru unknown
- 2005-04-27 US US11/117,139 patent/US20050277579A1/en not_active Abandoned
- 2005-04-27 MX MXPA06012685A patent/MXPA06012685A/es not_active Application Discontinuation
- 2005-04-27 AU AU2005244151A patent/AU2005244151A1/en not_active Abandoned
- 2005-04-27 JP JP2007511424A patent/JP2007536229A/ja active Pending
- 2005-04-27 BR BRPI0510593-5A patent/BRPI0510593A/pt not_active Application Discontinuation
- 2005-04-27 WO PCT/US2005/014629 patent/WO2005110405A1/en active Application Filing
- 2005-04-27 EP EP05741079A patent/EP1748776A1/en not_active Withdrawn
- 2005-04-27 CN CNA2005800173989A patent/CN1968692A/zh active Pending
- 2005-04-29 TW TW094113986A patent/TW200536553A/zh unknown
- 2005-05-02 AR ARP050101749A patent/AR048771A1/es unknown
-
2006
- 2006-11-01 IL IL178977A patent/IL178977A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL178977A0 (en) | 2007-03-08 |
MXPA06012685A (es) | 2007-01-16 |
BRPI0510593A (pt) | 2007-11-20 |
TW200536553A (en) | 2005-11-16 |
AU2005244151A1 (en) | 2005-11-24 |
JP2007536229A (ja) | 2007-12-13 |
US20050277579A1 (en) | 2005-12-15 |
CN1968692A (zh) | 2007-05-23 |
CA2565154A1 (en) | 2005-11-24 |
WO2005110405A1 (en) | 2005-11-24 |
RU2006139930A (ru) | 2008-06-10 |
EP1748776A1 (en) | 2007-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR048771A1 (es) | Composiciones para efectuar una perdida de peso | |
BRPI0506829A (pt) | composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso | |
AR046933A1 (es) | Eficacia de humectacion mejorada mediante el uso de hidroxialquilurea | |
AR050254A1 (es) | Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas | |
BRPI0414825A (pt) | processo e composição de alglutinante de ureìa-formaldeìdo | |
TR201908551T4 (tr) | Yakıt bileşimleri. | |
CL2008001656A1 (es) | Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene. | |
BRPI0509813A (pt) | protetor contra explosões e método para manusear um bloqueador de êmbolo percutor | |
CL2008002890A1 (es) | Composicion de combustible diesel que comprende un aditivo que es el producto de una reaccion de mannich entre un aldehido, una poliamina y un fenol opcionalmente sustituido; un paquete aditivo; y uso de dicho aditivo en una composicion de combustibl | |
ES2422556T3 (es) | Tratamiento de hepatitis vírica | |
WO2006107953A3 (en) | Reusable envelope structures and methods | |
BRPI0512878A (pt) | formulações de suspensão de aerossol, com tg 227 ea ou tg 134 a como agente propulsor | |
BRPI0507194A (pt) | processo para reduzir o conteúdo e cianeto de hidrogênio em misturas compreendendo penteno-nitrilas e cianeto e hidrogênio, e, uso de 1,3-butadieno | |
WO2009026497A3 (en) | Aggregate cutting saw chain | |
CL2008003712A1 (es) | Compuestos derivados de tiadiazololoxifenilamidina o tiazoliloxifenilamidina; su procedimiento de preparacion; uso y procedimiento para combatir microorganismos no deseados; agente que comprende a dichos compuestos; compuestos intermediarios; y su procedimiento de preparacion. | |
MX280211B (es) | Polimero, un metodo para producir el polimero y una mezcla de cemento que utiliza el mismo. | |
TW200738788A (en) | Polyorganosiloxane composition for use in unsaturated elastomer, article made therefrom, and associated method | |
CR9853A (es) | Compuestos de exemestano (s)-6-metiloxaalquilo y metodos relacionados con su utilizacion | |
CL2004000804A1 (es) | Procedimiento de preparacion en una sola etapa de n-(n'-glicilo substituida)-2-cianopirrolidina. | |
GT200600106A (es) | Agentes endoparasiticidas | |
AR056067A1 (es) | Procedimiento para la proteccion contra fitopatogenos mediante quiralaxil, uso correspondiente y agentes destinados a ese fin | |
AU301493S (en) | Reciprocating saw | |
DE50305442D1 (de) | Mitnehmer für kettenkratzförderer, insbesondere des untertagebetriebes | |
AR017233A1 (es) | Articulo absorbente sanitario que incluye una capa de componente que tiene una obstruccion para el flujo de fluido a traves de la capa. | |
AR031404A1 (es) | Una composicion y metodo de aplicacion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |